Disruption of nontuberculous mycobacteria biofilms induces a highly vulnerable to antibiotic killing phenotype

Kurbatfinski, Nikola; Hill, Preston J.; Tobin, Noah; Kramer, Cameron N.; Wickham, Joseph; Goodman, Steven D.; Hall-Stoodley, Luanne; Bakaletz, Lauren O.

doi:10.1016/j.bioflm.2023.100166

Cited by 2 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After biofilm formation these pegs can easily be transferred to another 96-wells plate containing a range of antibiotic concentrations, allowing the determination of the minimal biofilm eradication concentration by visual observation or by colony-forming units (CFU) determination, making it a more standardized approach compared to the microtiter plate method. Additionally, M. abscessus biofilms can be cultured in chambered slides ( Muñoz-Egea et al, 2016 ; Chakraborty et al, 2021 ; Yue et al, 2022 ; Kurbatfinski et al, 2023 ). With this method the biofilm is grown in individual wells on a chamber slide system, allowing for direct visualization of live bacteria using microscopy.…”

Section: Building the Biofilm Research Fundament—laboratory Models Us...mentioning

confidence: 99%

“…Clomiphene citrate, which is hypothesized to disrupt the mycobacterial membrane, and 10-DEBC, an inhibitor of the Akt pathway, inhibited the growth of 5-days old biofilms during a 4-day exposure (total assay duration of 9 days), but their killing activity was not assessed ( Lee et al, 2021 , 2022 ). 5-aminovulinic acid—photodynamic therapy, HuTipMab (targeting DNA binding proteins) and curcumin reduced biomass in established biofilms ( Marini et al, 2018 ; Yue et al, 2022 ; Kurbatfinski et al, 2023 ). In addition, curcumin enhanced the biofilm destructing capacity of amikacin in 4- and 8-day old biofilms ( Marini et al, 2018 ).…”

Section: Integrating Biofilm Techniques: Targeting the Myco...mentioning

confidence: 99%

See 1 more Smart Citation

A laboratory perspective on Mycobacterium abscessus biofilm culture, characterization and drug activity testing

Meliefste,

Mudde,

Ammerman

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

Mycobacterium abscessus is an emerging opportunistic pathogen causing severe pulmonary infections in patients with underlying lung disease and cystic fibrosis in particular. The rising prevalence of M. abscessus infections poses an alarming threat, as the success rates of available treatment options are limited. Central to this challenge is the absence of preclinical in vitro models that accurately mimic in vivo conditions and that can reliably predict treatment outcomes in patients. M. abscessus is notorious for its association with biofilm formation within the lung. Bacteria in biofilms are more recalcitrant to antibiotic treatment compared to planktonic bacteria, which likely contributes to the lack of correlation between preclinical drug activity testing (typically performed on planktonic bacteria) and treatment outcome. In recent years, there has been a growing interest in M. abscessus biofilm research. However, the absence of standardized methods for biofilm culture, biofilm characterization and drug activity testing has led to a wide spectrum of, sometimes inconsistent, findings across various studies. Factors such as strain selection, culture medium, and incubation time hugely impact biofilm development, phenotypical characteristics and antibiotic susceptibility. Additionally, a broad range of techniques are used to study M. abscessus biofilms, including quantification of colony-forming units, crystal violet staining and fluorescence microscopy. Yet, limitations of these techniques and the selected readouts for analysis affect study outcomes. Currently, research on the activity of conventional antibiotics, such as clarithromycin and amikacin, against M. abscessus biofilms yield ambiguous results, underscoring the substantial impact of experimental conditions on drug activity assessment. Beyond traditional drug activity testing, the exploration of novel anti-biofilm compounds and the improvement of in vitro biofilm models are ongoing. In this review, we outline the laboratory models, experimental variables and techniques that are used to study M. abscessus biofilms. We elaborate on the current insights of M. abscessus biofilm characteristics and describe the present understanding of the activity of traditional antibiotics, as well as potential novel compounds, against M. abscessus biofilms. Ultimately, this work contributes to the advancement of fundamental knowledge and practical applications of accurate preclinical M. abscessus models, thereby facilitating progress towards improved therapies for M. abscessus infections.

show abstract

Section: Building the Biofilm Research Fundament—laboratory Models Us...mentioning

confidence: 99%

Section: Integrating Biofilm Techniques: Targeting the Myco...mentioning

confidence: 99%

A laboratory perspective on Mycobacterium abscessus biofilm culture, characterization and drug activity testing

Meliefste,

Mudde,

Ammerman

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments

Liu,

Hu,

Wang

et al. 2024

IJMS

View full text Add to dashboard Cite

Tuberculosis (TB) remains a threat to human health worldwide. Mycobacterium tuberculosis (Mtb) and other nontuberculous mycobacteria (NTM) can form biofilms, and in vitro and animal experiments have shown that biofilms cause serious drug resistance and mycobacterial persistence. Deeper investigations into the mechanisms of mycobacterial biofilm formation and, consequently, the exploration of appropriate antibiofilm treatments to improve the efficiency of current anti-TB drugs will be useful for curing TB. In this review, the genes and molecules that have been recently reported to be involved in mycobacterial biofilm development, such as ABC transporter, Pks1, PpiB, GroEL1, MprB, (p)ppGpp, poly(P), and c-di-GMP, are summarized. Biofilm-induced clinical problems, including biofilm-related infections and enhanced virulence, as well as their possible mechanisms, are also discussed in detail. Moreover, we also illustrate newly synthesized anti-TB agents that target mycobacterial biofilm, as well as some assistant methods with high efficiency in reducing biofilms in hosts, such as the use of nanoparticles.

show abstract

Disruption of nontuberculous mycobacteria biofilms induces a highly vulnerable to antibiotic killing phenotype

Cited by 2 publications

References 39 publications

A laboratory perspective on Mycobacterium abscessus biofilm culture, characterization and drug activity testing

A laboratory perspective on Mycobacterium abscessus biofilm culture, characterization and drug activity testing

Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments

Contact Info

Product

Resources

About